Monocyte to High-density Lipoprotein Cholesterol Ratio Predicts Restenosis of Drug-eluting Stents in Patients with Unstable Angina Pectoris

Overview

Journal Sci Rep

Specialty Science

Date 2024 Dec 5

PMID 39632977

Authors

He Meng

Xiujun Zhou

Lushan Li

Yuanying Liu

Yujie Liu

Ying Zhang

Affiliations

Soon will be listed here.

Abstract

Several studies have shown that the monocyte count to high-density lipoprotein cholesterol ratio (MHR) serves as a predictive marker for in-stent restenosis (ISR) of bare-metal stents (BMSs). However, the ability of the MHR to predict ISR in patients with drug-eluting stents (DESs) remains uncertain. This study aimed to investigate the predictive value of the MHR for ISR in patients with unstable angina pectoris who have undergone primary DES implantation. A total of 474 consecutive patients with unstable angina pectoris who underwent successful DES-based percutaneous coronary intervention (PCI) from 01-12-2014 to 01-12-2022 were enrolled in the study. Patients were divided into the ISR group and the non-ISR group on the basis of the follow-up results of coronary angiography. The demographic and clinical characteristics of the patients were documented. The MHR was calculated via the following formula: [Formula: see text]. Multivariate logistic regression models were developed to evaluate the predictive value of the MHR for DES-ISR. The baseline MHR was notably greater in the ISR group than in the non-ISR group (P < 0.001). After adjusting for confounding factors, the MHR emerged as an independent predictor of ISR (OR = 1.244; 95%CI 1.171-1.321). Receiver operating characteristic (ROC) curve analysis revealed that MHR for predicting ISR had an AUC of 0.752 (95% CI 0.708-0.796). For a MHR > 7.32, the sensitivity was estimated to be 59.8% (95% CI 47.2-66.5%) and the specificity was 81.2% (95% CI 71.2-86.4%). Including the MHR in the predictive model for ISR improved the area under the curve (0.698 vs. 0.782, P < 0.001), categorical net reclassification improvement (0.703; 95%CI 0.536-0.871), and integrated discrimination improvement (0.121; 95%CI 0.092-0.151). The MHR can be used to predict DES-ISR in patients with unstable angina pectoris, indicating that the MHR may serve as a valuable marker for risk stratification and prognosis in individuals undergoing DES implantation.

References

Li C, Shen Y, Xu R, Dai Y, Chang S, Lu H . Evaluation of Preprocedural Laboratory Parameters as Predictors of Drug-Eluting Stent Restenosis in Coronary Chronic Total Occlusion Lesions. Angiology. 2018; 70(3):272-278. DOI: 10.1177/0003319717752245. View

Zeiher A, Schachinger V . Coronary endothelial vasodilator dysfunction: clinical relevance and therapeutic implications. Z Kardiol. 1994; 83 Suppl 4:7-14. View

Murphy A, Woollard K, Hoang A, Mukhamedova N, Stirzaker R, McCormick S . High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol. 2008; 28(11):2071-7. DOI: 10.1161/ATVBAHA.108.168690. View

Yilmaz S, Akboga M, Sen F, Balci K, Aras D, Temizhan A . Usefulness of the monocyte-to-high-density lipoprotein cholesterol ratio to predict bare metal stent restenosis. Biomark Med. 2016; 10(9):959-66. DOI: 10.2217/bmm-2016-0069. View

Akboga M, Balci K, Maden O, Goktug Ertem A, Kirbas O, Yayla C . Usefulness of monocyte to HDL-cholesterol ratio to predict high SYNTAX score in patients with stable coronary artery disease. Biomark Med. 2016; 10(4):375-83. DOI: 10.2217/bmm-2015-0050. View

Zhang Y, Li S, Guo Y, Wu N, Zhu C, Gao Y . Is monocyte to HDL ratio superior to monocyte count in predicting the cardiovascular outcomes: evidence from a large cohort of Chinese patients undergoing coronary angiography. Ann Med. 2016; 48(5):305-12. DOI: 10.3109/07853890.2016.1168935. View

Liu Y, Imanishi T, Ikejima H, Tsujioka H, Ozaki Y, Kuroi A . Association between circulating monocyte subsets and in-stent restenosis after coronary stent implantation in patients with ST-elevation myocardial infarction. Circ J. 2010; 74(12):2585-91. DOI: 10.1253/circj.cj-10-0544. View

Grewe P, Deneke T, Machraoui A, Barmeyer J, Muller K . Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol. 2000; 35(1):157-63. DOI: 10.1016/s0735-1097(99)00486-6. View

Byrne R, Rossello X, Coughlan J, Barbato E, Berry C, Chieffo A . [2023 ESC Guidelines for the management of acute coronary syndromes]. G Ital Cardiol (Rome). 2024; 25(2 Suppl 2):e1-e112. DOI: 10.1714/4191.41785. View

10.

Hirata A, Sugiyama D, Watanabe M, Tamakoshi A, Iso H, Kotani K . Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: The EPOCH-JAPAN study. J Clin Lipidol. 2018; 12(3):674-684.e5. DOI: 10.1016/j.jacl.2018.01.014. View

11.

Nesti L, Trico D, Mengozzi A, Natali A . Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovasc Diabetol. 2021; 20(1):109. PMC: 8130304. DOI: 10.1186/s12933-021-01294-7. View

12.

Welt F, Rogers C . Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002; 22(11):1769-76. DOI: 10.1161/01.atv.0000037100.44766.5b. View

13.

Seetharam D, Mineo C, Gormley A, Gibson L, Vongpatanasin W, Chambliss K . High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res. 2005; 98(1):63-72. DOI: 10.1161/01.RES.0000199272.59432.5b. View

14.

Alfonso F, Byrne R, Rivero F, Kastrati A . Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014; 63(24):2659-73. DOI: 10.1016/j.jacc.2014.02.545. View

15.

Mone P, Gambardella J, Minicucci F, Lombardi A, Mauro C, Santulli G . Hyperglycemia Drives Stent Restenosis in STEMI Patients. Diabetes Care. 2021; 44(11):e192-e193. PMC: 8546275. DOI: 10.2337/dc21-0939. View

16.

Ucar F . A potential marker of bare metal stent restenosis: monocyte count - to- HDL cholesterol ratio. BMC Cardiovasc Disord. 2016; 16(1):186. PMC: 5048646. DOI: 10.1186/s12872-016-0367-3. View

17.

Barter P, Kastelein J, Nunn A, Hobbs R . High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis. 2003; 168(2):195-211. DOI: 10.1016/s0021-9150(03)00006-6. View

18.

Kundi H, Kiziltunc E, Cetin M, Cicekcioglu H, Cetin Z, Cicek G . Association of monocyte/HDL-C ratio with SYNTAX scores in patients with stable coronary artery disease. Herz. 2016; 41(6):523-9. DOI: 10.1007/s00059-015-4393-1. View

19.

Byrne R, Joner M, Kastrati A . Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J. 2015; 36(47):3320-31. PMC: 4677274. DOI: 10.1093/eurheartj/ehv511. View

20.

Trimarco V, Izzo R, Morisco C, Mone P, Manzi M, Falco A . High HDL (High-Density Lipoprotein) Cholesterol Increases Cardiovascular Risk in Hypertensive Patients. Hypertension. 2022; 79(10):2355-2363. PMC: 9617028. DOI: 10.1161/HYPERTENSIONAHA.122.19912. View